Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Siplizumab - ITBMed Biopharmaceuticals

Drug Profile

Siplizumab - ITBMed Biopharmaceuticals

Alternative Names: MEDI-507; TCD 601

Latest Information Update: 27 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Catholic University of Louvain; Ossium Health
  • Developer BioTransplant (CEASED); ITBMed Biopharmaceuticals; Massachusetts General Hospital; MedImmune; Ossium Health
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Urologics
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Regulatory T-lymphocyte stimulants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver transplant rejection; Renal transplant rejection; Type 1 diabetes mellitus
  • Phase I/II Graft-versus-host disease; Transplant rejection
  • Discontinued Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; T-cell lymphoma

Most Recent Events

  • 25 Mar 2024 ITB-Med in collaboration with University of Alabama plans a phase-0 trial for Hidradenitis suppurativa in January 2025 (SC) (NCT06326476)
  • 09 Jan 2024 Phase-II clinical trials in Renal transplant rejection (Combination therapy, Prevention) in USA (IV) (NCT05669001)
  • 01 Oct 2023 Phase-I/II clinical trials in Renal transplant rejection in USA (IV) (NCT05900401)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top